This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moyer, A. M. Articles by Weinshilboum, R. M. Search for Related Content PubMed PubMed Citation Articles by Moyer, A. M. Articles by Weinshilboum, R. M.

Glutathione S-Transferase P1: Gene Sequence Variation and Functional Genomic Studies

¹ Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, ² Department of Biochemistry and Molecular Biology, and ³ Department of Health Sciences Research, Mayo Medical School-Mayo Clinic, Rochester, Minnesota

Requests for reprints: Richard Weinshilboum, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905. Phone: 507-284-2246; Fax: 507-284-4455; E-mail: weinshilboum.richard{at}mayo.edu.

Key Words: glutathione S-transferases • glutathione transferase • GST • GSTP1 • gene resequencing • functional genomics • genetic polymorphisms • SNPs • variant allozymes • expression regulation

Glutathione S-transferase P1 (GSTP1) is of importance for cancer research because of its role in detoxifying carcinogens, activating antineoplastic prodrugs, metabolizing chemotherapeutic agents, and its involvement in cell cycle and apoptosis regulation. Two common GSTP1 genetic polymorphisms have been studied extensively. However, the full range of GSTP1 genetic variation has not been systematically characterized in the absence of disease pathology. We set out to identify common GSTP1 polymorphisms in four ethnic groups, followed by functional genomic studies. All exons, splice junctions, and the 5'-flanking region of GSTP1 were resequenced using 60 DNA samples each from four ethnic groups. The 35 single-nucleotide polymorphisms (SNP) identified included six nonsynonymous SNPs and 17 previously unreported polymorphisms. GSTP1 variant allozymes were then expressed in COS-1 cells, and five displayed significantly altered levels of enzyme activity. One decreased to 22% of the wild-type (WT) activity. Four variant allozymes had K_m values that differed significantly from that of the WT, and five showed altered levels of immunoreactive protein compared with WT, with a significant correlation (r = 0.79, P < 0.007) between levels of immunoreactive protein and enzyme activity in these samples. In the Mexican American population, five linked SNPs were significantly associated with GSTP1 mRNA expression, one of which was found by electrophoretic mobility shift assay to alter protein binding. These studies have identified functionally significant genetic variation, in addition to the two frequently studied GSTP1 nonsynonymous SNPs, that may influence GSTP1's contribution to carcinogen and drug metabolism, and possibly disease pathogenesis and/or drug response. [Cancer Res 2008;68(12):4791–801]

This article has been cited by other articles:

				N. Niu, V. Manickam, K. R. Kalari, I. Moon, L. L. Pelleymounter, B. W. Eckloff, E. D. Wieben, D. J. Schaid, and L. Wang Human Glucocorticoid Receptor {alpha} Gene (NR3C1) Pharmacogenomics: Gene Resequencing and Functional Genomics J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 3072 - 3084. [Abstract] [Full Text] [PDF]